Qpex Biopharma Announces Publication of Data in Nature Communications on the New Synthetic Lipopeptide Antibiotic QPX9003 Targeting Multidrug-Resistant Gram-negative Pathogens

SAN DIEGO–(BUSINESS WIRE)–Qpex Biopharma, Inc., (Qpex) an antibiotic resistance-focused clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, today announced research published in Nature Communications on the discovery and preclinical properties of QPX9003, a new synthetic lipopeptide antibiotic that is distinct from existing polymyxin-type antibiotics. The paper, “A synthetic lipopeptide targeting top-priority multidrug-resistant gram-negati
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks